Native amylin has awkward physical properties — it aggregates readily, which is why a stable analogue is a pharmaceutical achievement rather than a formulation detail.
If the premise is wrong, everything after it is decoration.
25 likes 5mo
Topic summary
[2026 update] Amylin and gastric emptying: overlapping mechanisms with incretins
This is a generated summary. It shows the 5 most-liked posts from a topic of 26, in their original order, with the accepted answer included where one exists. It is a reading aid and it will miss nuance — the full topic is the record.
Historical amylin analogues: pramlintide was the only long-acting amylin analogue licensed for some time and its poor adherence was a known limitation. A weekly formulation addresses that practical barrier.
18 likes 5mo
Answering the question post #7 raises rather than the one it answers.
On Amylin and gastric emptying, the part that usually goes wrong is that the question is asked as though it has one answer. It has a range, and the width of the range is the interesting bit.
If you can post the two or three numbers you are working from, several people here will check the arithmetic rather than argue about the conclusion.
26 likes 5mo
n.serrano, post #9: Answering the question post #7 raises rather than the one it answers. On Amylin and gastric emptying, the part that usually goes wrong is that the question is asked as though it has one answer. It has a range, and the width of the range is the interesting bit. If you can post the two or three numbers you are working from, several people… Go to post
Adding the measurement that post #12 says would settle it.
Amylin analogues affect gastric emptying as well, so the mechanism overlaps the incretins in at least one place. That overlap is part of why the combination's tolerability profile is not simply the sum of the two.
I have left out the parts I could not verify.
Post #19 describes the usual case. This is about the unusual one.
Research-use-only cagrilintide is not approved for human use and the published evidence base is a clinical-trial evidence base. Those two facts sit uncomfortably together and both are true.
Posting it because the silence on this was starting to look like agreement.
27 likes 5mo
Read the full topic (26 posts)
This topic was referenced in
- Why cagrilintide alone is discussed so much less than in combinationCompounds › Cagrilintide & amylin analogues · 108 replies
- The CagriSema phase 2 paper and what a fixed combination buys — the long versionCompounds › Cagrilintide & amylin analogues · 158 replies
- Why cagrilintide alone is discussed so much less than in combination — does this still hold?Compounds › Cagrilintide & amylin analogues · 31 replies
Suggested topics
| Topic | Participants | Replies | Views | Activity |
|---|---|---|---|---|
|
Amylin analogue mechanism: satiety signalling separate from GLP-1 — does this still hold?
Amylin analogue mechanism: satiety signalling separate from GLP-1 — does this still hold? — that is the question, and I have not found it answered plainly anywhere I have looked. Trying to work out what would…
|
+21 | 25 | 45k | 7mo |
|
Cagrilintide's dosing interval and the pharmacokinetics behind it
Cagrilintide's dosing interval and the pharmacokinetics behind it — setting out what I have, and where I think it stops being reliable. Putting the numbers in the first post, because a question about a…
|
+98 | 105 | 24k | 10mo |
|
Historical amylin analogues and what happened to them
Posting this under the heading it deserves: Historical amylin analogues and what happened to them Everything below is what sits behind that. Proposing that historical amylin analogues deserves a maintained…
|
+29 | 36 | 31k | 1d |
|
Is "synergy" the right word for the combination data?
Is "synergy" the right word for the combination data? — that is the question, and I have not found it answered plainly anywhere I have looked. Setting out what I think I know about this compound and asking…
|
+5 | 9 | 13k | 25d |
|
Second pass at: Reading a combination trial: attributing effect to components
Second pass at: Reading a combination trial: attributing effect to components — setting out what I have, and where I think it stops being reliable. The question about Reading a combination trial that I…
|
+39 | 43 | 7.3k | 12mo |
Related topics — sharing the tags amylin analogues, randomised trial, effect size
| Topic | Participants | Replies | Views | Activity |
|---|---|---|---|---|
|
Second pass at: When a network meta-analysis is defensible and when it is not
Posting this under the heading it deserves: Second pass at: When a network meta-analysis is defensible and when it is not Everything below is what sits behind that. Posting a small dataset on network…
|
2 | 2.8k | 21mo | |
|
Journal club: SELECT, absolute risk, and how it was reported
Journal club: SELECT, absolute risk, and how it was reported Writing it up because I had to work it out twice and would rather nobody else did. A question about what the numbers mean rather than what they…
|
2 | 52k | 1mo | |
|
Coming back to: The SOUL trial and oral semaglutide cardiovascular outcomes
The SOUL trial and oral semaglutide cardiovascular outcomes — setting out what I have, and where I think it stops being reliable. SOUL trial and oral semaglutide — I have the observation and I do not trust my…
|
+100 | 104 | 4.2k | 5mo |
|
Oral semaglutide bioavailability and its variability between people — a second dataset
Oral semaglutide bioavailability and its variability between people — a second dataset — setting out what I have, and where I think it stops being reliable. Posting a small dataset on Oral semaglutide…
|
+141 | 154 | 47k | 19mo |
|
Oral versus injectable exposure: comparing apples to a different fruit — a second dataset
Posting this under the heading it deserves: Oral versus injectable exposure: comparing apples to a different fruit — a second dataset Everything below is what sits behind that. Something about Oral versus…
|
+27 | 31 | 17k | 25d |